Manipulating the Tumor Microenvironment by Adoptive Cell Transfer of CAR T-cells

Overview

Journal Mamm Genome

Specialty Genetics

Date 2018 Jul 11

PMID 29987406

Citations 16

Authors

Kavitha Gowrishankar

Lucy Birtwistle

Kenneth Micklethwaite

Affiliations

Soon will be listed here.

Abstract

T-cells expressing synthetic chimeric antigen receptors (CARs) have revolutionized immuno-oncology and highlighted the use of adoptive cell transfer, for the treatment of cancer. The phenomenal clinical success obtained in the treatment of hematological malignancies with CAR T-cells has not been reproduced in the treatment of solid tumors, mainly due to the suppressive and hostile tumor microenvironment (TME). This review will address the immunosuppressive features of the TME, which include the stroma, cytokine and chemokine milieu, suppressive regulatory cells and hypoxic conditions, which can all pose formidable barriers for the effective anti-tumor function of CAR T-cells. Some of the novel next generation CARs that have been developed and tested against the TME, will be discussed, to highlight the status of current research in CAR T-cell therapy for solid tumors.

Citing Articles

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies.

Su M, Zhang Z, Jiang P, Wang X, Tong X, Wu G Cell Transplant. 2024; 33:9636897241293964.

PMID: 39506457 PMC: 11693693. DOI: 10.1177/09636897241293964.

T cell effects and mechanisms in immunotherapy of head and neck tumors.

Xiang Y, Gong M, Deng Y, Wang H, Ye D Cell Commun Signal. 2023; 21(1):49.

PMID: 36872320 PMC: 9985928. DOI: 10.1186/s12964-023-01070-y.

Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer.

Zhu Y, Zhou J, Zhu L, Hu W, Liu B, Xie L Hum Vaccin Immunother. 2022; 18(5):2060019.

PMID: 35468048 PMC: 9897649. DOI: 10.1080/21645515.2022.2060019.

Graft-Versus-Solid-Tumor Effect: From Hematopoietic Stem Cell Transplantation to Adoptive Cell Therapies.

Barisic S, Childs R Stem Cells. 2022; 40(6):556-563.

PMID: 35325242 PMC: 9216497. DOI: 10.1093/stmcls/sxac021.

References

Beavis P, Henderson M, Giuffrida L, Mills J, Sek K, Cross R . Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017; 127(3):929-941. PMC: 5330718. DOI: 10.1172/JCI89455. View

Scharping N, Menk A, Moreci R, Whetstone R, Dadey R, Watkins S . The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity. 2016; 45(3):701-703. DOI: 10.1016/j.immuni.2016.08.009. View

Jiang H, Hegde S, Knolhoff B, Zhu Y, Herndon J, Meyer M . Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016; 22(8):851-60. PMC: 4935930. DOI: 10.1038/nm.4123. View

Beecham E, Junghans R . Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor. J Immunother. 2000; 23(3):332-43. DOI: 10.1097/00002371-200005000-00006. View

Morsut L, Roybal K, Xiong X, Gordley R, Coyle S, Thomson M . Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell. 2016; 164(4):780-91. PMC: 4752866. DOI: 10.1016/j.cell.2016.01.012. View

Koneru M, OCearbhaill R, Pendharkar S, Spriggs D, Brentjens R . A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med. 2015; 13:102. PMC: 4438636. DOI: 10.1186/s12967-015-0460-x. View

Koneru M, Purdon T, Spriggs D, Koneru S, Brentjens R . IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors . Oncoimmunology. 2015; 4(3):e994446. PMC: 4404840. DOI: 10.4161/2162402X.2014.994446. View

Lanitis E, Poussin M, Klattenhoff A, Song D, Sandaltzopoulos R, June C . Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2014; 1(1):43-53. PMC: 3881605. DOI: 10.1158/2326-6066.CIR-13-0008. View

Turtle C, Hanafi L, Berger C, Hudecek M, Pender B, Robinson E . Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016; 8(355):355ra116. PMC: 5045301. DOI: 10.1126/scitranslmed.aaf8621. View

10.

Dudley M, Rosenberg S . Adoptive cell transfer therapy. Semin Oncol. 2007; 34(6):524-31. PMC: 2198934. DOI: 10.1053/j.seminoncol.2007.09.002. View

11.

Zhang L, Kerkar S, Yu Z, Zheng Z, Yang S, Restifo N . Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011; 19(4):751-9. PMC: 3070103. DOI: 10.1038/mt.2010.313. View

12.

Chodon T, Comin-Anduix B, Chmielowski B, Koya R, Wu Z, Auerbach M . Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014; 20(9):2457-65. PMC: 4070853. DOI: 10.1158/1078-0432.CCR-13-3017. View

13.

Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G . Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015; 125(25):3905-16. PMC: 4473118. DOI: 10.1182/blood-2015-01-621474. View

14.

Junghans R, Ma Q, Rathore R, Gomes E, Bais A, Lo A . Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. Prostate. 2016; 76(14):1257-70. DOI: 10.1002/pros.23214. View

15.

Andersen R, Westergaard M, Kjeldsen J, Muller A, Pedersen N, Hadrup S . T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy. Cancer Immunol Res. 2018; 6(2):222-235. DOI: 10.1158/2326-6066.CIR-17-0467. View

16.

Theocharis A, Skandalis S, Gialeli C, Karamanos N . Extracellular matrix structure. Adv Drug Deliv Rev. 2015; 97:4-27. DOI: 10.1016/j.addr.2015.11.001. View

17.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

18.

Fu X, Rivera A, Tao L, Zhang X . Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery. Int J Cancer. 2013; 133(10):2483-92. PMC: 3770832. DOI: 10.1002/ijc.28269. View

19.

Ferrara N, Alitalo K . Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999; 5(12):1359-64. DOI: 10.1038/70928. View

20.

Beezhold K, Byersdorfer C . Targeting immuno-metabolism to improve anti-cancer therapies. Cancer Lett. 2017; 414:127-135. PMC: 6447063. DOI: 10.1016/j.canlet.2017.11.005. View